BONUSCAP-ZERTIFIKAT - NOVO-NORDISK B | Market Closed - BOERSE MUENCHEN 20:46:59 14/06/2024 BST | ||
| 883.7 EUR | +0.04% |
|
| Current month | +0.40% | ||
| 1 month | +1.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 883.7 | +0.04% |
| 13/06/24 | 883.4 | +0.14% |
| 12/06/24 | 882.1 | +0.02% |
| 11/06/24 | 882 | -0.08% |
| 10/06/24 | 882.7 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 08:46 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD0CHA |
| ISIN | DE000HD0CHA8 |
| Date issued | 01/11/2023 |
| Strike | 900 kr |
| Maturity | 20/12/2024 (188 Days) |
| Parity | 1 : 1 |
| Emission price | 725.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 883.7 € |
|---|---|
| Lowest since issue | 696.4 € |
| Spread | 1.86 € |
| Spread % | 0.21% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
